Verona Pharma plc — Director's Dealing 2022

Nov 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-11-01

Reporting Person: Hahn Mark W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-01	Ordinary Shares	F	454856	$1.6	Disposed	17458640	Direct
2022-11-01	Ordinary Shares	S	13160	$1.6726	Disposed	17445480	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.

F3: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8).

F4: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.

F5: The price reported represents the sale price of the ADSs divided by eight (8).

F6: Consists of (i) 9,413,016 Ordinary Shares underlying RSUs (which are represented by 1,176,627 ADSs); and (ii) 8,032,464 Ordinary Shares underlying 1,004,058 ADSs.